newsfilter
← Latest News
Business Wire·

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

QGEN
  • QIAGEN reported Q2 2026 net sales of $535 million, unchanged from Q2 2025 on a reported basis & at constant exchange rates (CER), exceeding the outlook for a 2% CER decline.
  • Growth pillars delivered approximately 5% CER growth, led by Sample technologies, QIAcuity, & QIAGEN Digital Insights (QDI).
  • QuantiFERON sales rose 1% CER despite lower U.S. immigration testing demand.
  • Adjusted operating income margin remained at 29.4%, maintaining a high level of profitability.
  • Diluted EPS was $0.50, while adjusted diluted EPS reached $0.62 on both reported & CER bases, surpassing the $0.60 CER outlook.
  • H1 2026 operating cash totaled $301 million, remaining at a strong level compared to H1 2025.
  • The company reaffirmed its full-year 2026 outlook for net sales growth of 1-2% CER & adjusted diluted EPS of at least $2.43 CER.
  • QIAGEN increased its 2026 dividend by 40% compared with 2025.
  • A conference call is scheduled for August 6, 2026, at 15:30 Frankfurt Time / 14:30 London Time / 09:30 New York Time.
  • QIAGEN employs approximately 5,500 people across more than 35 locations globally as of June 30, 2026.